Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
69
OCUL Quote, Financials, Valuation and Earnings
Last price:
$14.18
Seasonality move
:
37.03%
Day range:
$14.35 - $15.38
52-week range:
$5.79 - $16.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
45.28x
P/B ratio:
12.01x
Volume:
2.8M
Avg. volume:
3.2M
1-year change:
63.78%
Market cap:
$3.1B
Revenue:
$63.7M
EPS (TTM):
-$1.44
Analysts' Opinion
-
Consensus RatingOcular Therapeutix, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.17, Ocular Therapeutix, Inc. has an estimated upside of 65.98% from its current price of $14.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.00 representing 100% downside risk from its current price of $14.56.
Fair Value
-
According to the consensus of 8 analysts, Ocular Therapeutix, Inc. has 65.98% upside to fair value with a price target of $24.17 per share.
OCUL vs. S&P 500
-
Over the past 5 trading days, Ocular Therapeutix, Inc. has overperformed the S&P 500 by 16.47% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ocular Therapeutix, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ocular Therapeutix, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Ocular Therapeutix, Inc. reported revenues of $14.5M.
Earnings Growth
-
Ocular Therapeutix, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Ocular Therapeutix, Inc. reported earnings per share of -$0.38.
Enterprise value:
2.8B
EV / Invested capital:
8.45x
Price / LTM sales:
45.28x
EV / EBIT:
--
EV / Revenue:
50.81x
PEG ratio (5yr expected):
-1.15x
EV / Free cash flow:
-14.21x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$49.6M
Return On Assets:
-56.32%
Net Income Margin (TTM):
-447.58%
Return On Equity:
-83.37%
Return On Invested Capital:
-66.46%
Operating Margin:
-472.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $57.7M | $61.4M | $55.8M | $15.4M | $14.5M | |
| Gross Profit | $52.8M | $55.7M | $49.6M | $13.9M | $12.8M | |
| Operating Income | -$81.7M | -$141.3M | -$250.8M | -$46M | -$68.7M | |
| EBITDA | -$79.2M | -$137.5M | -$246.8M | -$45M | -$67.6M | |
| Diluted EPS | -$1.11 | -$1.32 | -$1.44 | -$0.22 | -$0.38 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $203.9M | $145.6M | $141.3M | $473M | $387M | |
| Total Assets | $217.7M | $158.6M | $162.4M | $490.4M | $410.9M | |
| Current Liabilities | $25.2M | $29.3M | $35.1M | $36.4M | $49.3M | |
| Total Liabilities | $130.4M | $112.4M | $154.5M | $138.3M | $152.7M | |
| Total Equity | $87.3M | $46.2M | $7.9M | $352M | $258.2M | |
| Total Debt | $51.2M | $49.5M | $81.1M | $73.4M | $74.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$69.9M | -$112.5M | -$190.1M | -$36.6M | -$50.7M | |
| Cash From Investing | -$7.8M | -$1.5M | -$9.2M | -$89K | -$6M | |
| Cash From Financing | $67.3M | $430.6M | $116.9M | $4.2M | $10.4M | |
| Free Cash Flow | -$77.7M | -$114.1M | -$199.4M | -$36.6M | -$56.7M | |
OCUL
Sector
Market Cap
$3.1B
$29M
Price % of 52-Week High
88.56%
52.89%
Dividend Yield
0%
0%
Shareholder Yield
9.73%
-1.4%
1-Year Price Total Return
63.78%
-19%
Beta (5-Year)
0.962
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.15
200-day SMA
Buy
Level
$10.19
Bollinger Bands (100)
Buy
Level
11.22 - 13.08
Chaikin Money Flow
Sell
Level
-43M
20-day SMA
Buy
Level
$12.78
Relative Strength Index (RSI14)
Buy
Level
63.30
ADX Line
Buy
Level
28.34
Williams %R
Neutral
Level
-35.5052
50-day SMA
Buy
Level
$12.00
MACD (12, 26)
Buy
Level
0.88
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
95.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.893)
Sell
CA Score
(Annual)
Level (-2.2438)
Buy
Beneish M-Score
(Annual)
Level (-2.9903)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (2.0254)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Stock Forecast FAQ
In the current month, OCUL has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OCUL average analyst price target in the past 3 months is $24.17.
-
Where Will Ocular Therapeutix, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ocular Therapeutix, Inc. share price will rise to $24.17 per share over the next 12 months.
-
What Do Analysts Say About Ocular Therapeutix, Inc.?
Analysts are divided on their view about Ocular Therapeutix, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ocular Therapeutix, Inc. is a Sell and believe this share price will drop from its current level to $19.00.
-
What Is Ocular Therapeutix, Inc.'s Price Target?
The price target for Ocular Therapeutix, Inc. over the next 1-year time period is forecast to be $24.17 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OCUL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ocular Therapeutix, Inc. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OCUL?
You can purchase shares of Ocular Therapeutix, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ocular Therapeutix, Inc. shares.
-
What Is The Ocular Therapeutix, Inc. Share Price Today?
Ocular Therapeutix, Inc. was last trading at $14.18 per share. This represents the most recent stock quote for Ocular Therapeutix, Inc.. Yesterday, Ocular Therapeutix, Inc. closed at $14.56 per share.
-
How To Buy Ocular Therapeutix, Inc. Stock Online?
In order to purchase Ocular Therapeutix, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get OCUL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
OCUL
Sector
P/E ratio
--
24.19x
PEG ratio
-1.15x
-0.01x
P/B ratio
12.01x
1.84x
Price / LTM sales
45.28x
1.61x
Growth Metrics
OCUL
Sector
Revenue growth
-5.71%
4.6%
Earnings growth
-72.72%
10.88%
Revenue (5-year growth)
72.05%
6.5%
Earnings forecast
-$0.35
-$0.20
Profitability
OCUL
Sector
Profitability FY 2024
$58.1M
$3.5M
Return on invested capital
-66.46%
-31.66%
Return on assets
-56.32%
-27.84%
Return on equity
-83.37%
-37.15%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
3
Balance Sheet
OCUL
Sector
Total cash
$344.8M
$26.8M
Short term investments
--
$26M
Total assets
$457.9M
$79.7M
Long term debt
$74.2M
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 3.51% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.79% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 5.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
